Why the study?
Data regarding correlations between arterial velocity pulse index and heart failure are limited, prompting evaluation of its clinical significance in stage B HFpEF.
Does arterial velocity pulse index (AVI) correlate with clinical parameters of disease severity in patients with stage B HFpEF?
Does arterial velocity pulse index (AVI) correlate with clinical parameters of disease severity in patients with stage B HFpEF?
Arterial velocity pulse index (AVI) significantly correlates with markers of diastolic dysfunction, myocardial injury, oxidative stress, kidney function, and muscle mass in patients with asymptomatic stage B HFpEF.
Answers are grounded in this paper and cite their sources.
AVI may reflect subclinical changes in stage B HFpEF but should not yet change practice; hypothesis-generating and requires prospective validation.
BACKGROUND: In clinical settings, the arterial velocity pulse index (AVI) is explored as a novel marker of atherosclerosis using pulse wave analysis; however, data regarding the correlations between AVI and heart failure (HF) are limited. This study aimed to elucidate the clinical significance of AVI in patients with stage B HF with preserved ejection fraction (HFpEF). METHODS: In this cross-sectional study, 345 patients with stage B HFpEF (no symptoms despite evidence of cardiac structural or functional impairment, and left ventricular ejection fraction which is estimated by echocardiography ≥ 50%) were enrolled. Patients with a history of HF hospitalization were excluded. The AVI was measured using a commercial device, and associations between AVI and various clinical parameters were examined. RESULTS: Significant correlations between AVI and various clinical parameters, such as E/e' as a maker of left ventricular diastolic function (r = 0.35; P < 0.001), high-sensitivity cardiac troponin T levels as a marker of myocardial injury (r = 0.47; P < 0.001), reactive oxygen metabolite levels as an oxidative stress marker (r = 0.31; P < 0.001), urinary albumin concentration as a marker of kidney function (r = 0.34; P < 0.001) and calf circumference as a marker of muscle mass volume (r = -0.42; P < 0.001) were observed. Furthermore, multiple regression analyses revealed that these clinical parameters were selected as independent variables when AVI was used as a subordinate factor. CONCLUSIONS: This study shows that AVI might be a determining factor for prognosis in patients with stage B HFpEF. Nevertheless, further comprehensive prospective studies, including intervention therapies, are warranted to validate the findings of this study.
No takes yet. Share an insight, caveat, or question.
Takashi Hitsumoto (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: